Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 13/20 | 0.83 |
| ▸ | AKT1 | P31749 | 2/20 | 0.83 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.81 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | CDC42BPA | Q5VT25 | 6/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987562 | 0.91 | ROCK2 (0.84) | ROCK2AKT1ROCK1RPS6KB1NPC1 | |
| SCHEMBL1988483 | 0.91 | ROCK2 (1.00) | ROCK2AKT1ROCK1RPS6KB1NPC1 | |
| SCHEMBL1988490 | 0.91 | ROCK2 (1.00) | ROCK2AKT1ROCK1RPS6KB1NPC1 | |
| SCHEMBL1990233 | 0.91 | ROCK2 (0.83) | ROCK2AKT1ROCK1RPS6KB1NPC1 | |
| Sr-3677 SCHEMBL453528 | 0.90 | ROCK2 (1.00) | ROCK2AKT1ROCK1RPS6KB1CDC42BPA | |
| Sr-3677 SCHEMBL22145950 | 0.90 | ROCK2 (1.00) | ROCK2AKT1ROCK1RPS6KB1CDC42BPA | |
| Sr-3677 SCHEMBL29378608 | 0.90 | ROCK2 (1.00) | ROCK2AKT1ROCK1RPS6KB1CDC42BPA | |
| Sr-3677 SCHEMBL15842050 | 0.89 | ROCK2 (0.98) | ROCK2AKT1ROCK1RPS6KB1CDC42BPA | |
| Sr-3677 SCHEMBL30373321 | 0.89 | ROCK2 (0.98) | ROCK2AKT1ROCK1RPS6KB1CDC42BPA | |
| Sr-3677 SCHEMBL29249231 | 0.89 | ROCK2 (0.98) | ROCK2AKT1ROCK1RPS6KB1CDC42BPA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110150833-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110150833-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110150833-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2009079008-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | FENG YANGBO (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150833-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | ROCK1, RHOA, RHOT2 | ROCK2 4/4885AKT1 31/4885ROCK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.